​

Aardvark Therapeutics (AARD) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

AARD Stock Forecast


Aardvark Therapeutics (AARD) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $2.40, with a high of $4.00 and a low of $1.50. This represents a 108.70% increase from the last price of $1.15.

- $3 $6 $9 $12 $15 High: $4 Avg: $2.4 Low: $1.5 Last Closed Price: $1.15

AARD Stock Rating


Aardvark Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (50.00%), 4 Hold (40.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 4 5 Strong Sell Sell Hold Buy Strong Buy

AARD Price Target Upside V Benchmarks


TypeNameUpside
StockAardvark Therapeutics108.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts559
Avg Price Target$2.40$2.40$11.44
Last Closing Price$1.15$1.15$1.15
Upside/Downside108.70%108.70%894.78%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26-541111
Oct, 26-641112
Sep, 26-641112
Aug, 26-641112
Jul, 26-641112
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 16, 2026James CondulisStifel Nicolaus$2.00$1.2955.04%73.91%
Oct 26, 2026Raghuram SelvarajuH.C. Wainwright$2.00$1.3943.88%73.91%
Oct 23, 2026RBC Capital$2.50$1.7245.35%117.39%
Oct 19, 2026UBS$4.00$3.785.82%247.83%
May 15, 2026Morgan Stanley$3.00$6.73-55.42%160.87%
Mar 02, 2026Brian AbrahamsRBC Capital$6.00$12.49-51.96%421.74%
Jan 12, 2026Chris RaymondRaymond James$47.00$14.27229.36%3986.96%
Dec 23, 2025Leland GershellOppenheimer$35.00$14.55140.55%2943.48%
Nov 14, 2025Brian AbrahamsRBC Capital$18.00$10.8665.75%1465.22%
Sep 29, 2025Stifel Nicolaus$24.00$13.2381.41%1986.96%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2026Raymond JamesMarket PerformMarket Performhold
Nov 04, 2026Raymond JamesStrong BuyMarket Performdowngrade
Oct 26, 2026OppenheimerOutperformPerformdowngrade
Oct 26, 2026H.C. WainwrightHoldHoldhold
May 15, 2026B. RileyBuyBuyhold
May 15, 2026BTIGHolddowngrade
May 15, 2026Morgan StanleyOverweightUnderweightdowngrade
Mar 24, 2026B. RileyBuyBuyhold
Mar 02, 2026H.C. WainwrightNeutraldowngrade
Mar 02, 2026RBC CapitalOutperformSector Performdowngrade

Financial Forecast


EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.59$-2.93----
Avg Forecast$-2.86$-2.63$-2.57$-2.92$-1.89$-0.79
High Forecast$-2.86$-1.62$-2.50$-2.92$-1.89$-0.79
Low Forecast$-2.86$-3.68$-2.70$-2.92$-1.89$-0.79
Surprise %-44.41%11.41%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast--$750.00K$20.09M$116.36M$241.16M
High Forecast--$750.00K$20.09M$116.36M$241.16M
Low Forecast--$750.00K$20.09M$116.36M$241.16M
Surprise %------

Net Income Forecast

$-60M $-50M $-40M $-30M $-20M $-10M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-20.59M$-57.59M----
Avg Forecast$-36.86M$-33.97M$-33.55M$-37.70M$-24.33M$-10.13M
High Forecast$-36.86M$-20.97M$-32.24M$-37.70M$-24.33M$-10.13M
Low Forecast$-36.86M$-47.54M$-34.85M$-37.70M$-24.33M$-10.13M
Surprise %-44.14%69.53%----

AARD Forecast FAQ


Is Aardvark Therapeutics stock a buy?

Aardvark Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Aardvark Therapeutics is a favorable investment for most analysts.

What is Aardvark Therapeutics's price target?

Aardvark Therapeutics's price target, set by 10 Wall Street analysts, averages $2.4 over the next 12 months. The price target range spans from $1.5 at the low end to $4 at the high end, suggesting a potential 108.70% change from the previous closing price of $1.15.

How does Aardvark Therapeutics stock forecast compare to its benchmarks?

Aardvark Therapeutics's stock forecast shows a 108.70% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aardvark Therapeutics over the past three months?

  • November 2026: 0% Strong Buy, 45.45% Buy, 36.36% Hold, 9.09% Sell, 9.09% Strong Sell.
  • October 2026: 0% Strong Buy, 50.00% Buy, 33.33% Hold, 8.33% Sell, 8.33% Strong Sell.
  • September 2026: 0% Strong Buy, 50.00% Buy, 33.33% Hold, 8.33% Sell, 8.33% Strong Sell.

What is Aardvark Therapeutics’s EPS forecast?

Aardvark Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.57, marking a -12.29% decrease from the reported $-2.93 in 2025. Estimates for the following years are $-2.92 in 2027, $-1.89 in 2028, and $-0.79 in 2029.

What is Aardvark Therapeutics’s revenue forecast?

Aardvark Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $750K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $20.09M, followed by $116.36M for 2028, and $241.16M for 2029.

What is Aardvark Therapeutics’s net income forecast?

Aardvark Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-33.547M, representing a -41.75% decrease from the reported $-57.591M in 2025. Projections indicate $-37.695M in 2027, $-24.334M in 2028, and $-10.134M in 2029.